$PCLA

PicoCELA Inc.

No enriched coverage for $PCLA in the last 7 days.

No SEC Form 4 filings for $PCLA in the last 30 days.

Med

PicoCELA Shareholders Approve Capital Restructuring, Charter Changes and Long-Term Director Stock Plan

PicoCELA shareholders approved a capital restructuring plan on February 24, 2026, including erasing ¥1.38 billion in accumulated deficit and expanding authorized shares to 16.6 million. These measures aim to strengthen the company's balance sheet and increase funding flexibility. Additionally, a 30-year restricted stock compensation program for directors was approved, designed to align their incentives with long-term corporate value.

PicoCELA Shareholders Approve Reverse Stock Split and Director Equity Compensation at 2025 AGM

PicoCELA Inc. shareholders approved a reverse stock split and director share compensation at their annual general meeting on December 29, 2025. The reverse stock split, taking effect January 26, 2026, will proportionally reduce outstanding shares and ADSs without impacting individual ADS holders' economic interests, aiming to support the company's market profile. Additionally, directors will receive share-based compensation, aligning their incentives with shareholder value.